<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326090</url>
  </required_header>
  <id_info>
    <org_study_id>CL12002 / 14-110-0005</org_study_id>
    <nct_id>NCT02326090</nct_id>
  </id_info>
  <brief_title>Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1.0% and 2.5% Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herantis Pharma Plc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Herantis Pharma Plc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the Phase 2 study is to compare the safety and efficacy of cis-UCA&#xD;
      Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal Fluorescein Staining</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom Score</measure>
    <time_frame>Day 22 to 28</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>cis-UCA ophthalmic solution 1.0%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop in each eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cis-UCA ophthalmic solution 2.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop in each eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ophthalmic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop in each eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cis-UCA ophthalmic solution 1.0%</intervention_name>
    <arm_group_label>cis-UCA ophthalmic solution 1.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cis-UCA ophthalmic solution 2.5%</intervention_name>
    <arm_group_label>cis-UCA ophthalmic solution 2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ophthalmic solution</intervention_name>
    <arm_group_label>Placebo ophthalmic solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years of age;&#xD;
&#xD;
          -  Provide written informed consent;&#xD;
&#xD;
          -  Have a subject reported history of dry eye;&#xD;
&#xD;
          -  Have a history of use or desire to use eye drops.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Have any clinically significant eye findings that require therapeutic treatment,&#xD;
             and/or in the opinion of the Investigator may interfere with study parameters;&#xD;
&#xD;
          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses&#xD;
             during the study;&#xD;
&#xD;
          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the&#xD;
             last 12 months;&#xD;
&#xD;
          -  Have used RestasisÂ® within 30 days of Visit 1;&#xD;
&#xD;
          -  Have any planned ocular and/or lid surgeries over the study period;&#xD;
&#xD;
          -  Be a woman who is pregnant, nursing or planning a pregnancy;&#xD;
&#xD;
          -  Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 4 (or early&#xD;
             termination visit) if of childbearing potential;&#xD;
&#xD;
          -  Have a known allergy and/or sensitivity to the study drug or its components;&#xD;
&#xD;
          -  Have a condition or be in a situation which the Investigator feels may put the subject&#xD;
             at significant risk, may confound the study results, or may interfere significantly&#xD;
             with the subject's participation in the study;&#xD;
&#xD;
          -  Be currently enrolled in an investigational drug or device study or have used an&#xD;
             investigational drug or device within 30 days of Visit 1;&#xD;
&#xD;
          -  Be unable or unwilling to follow instructions, including participation in all study&#xD;
             assessments and visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2014</study_first_posted>
  <last_update_submitted>September 7, 2015</last_update_submitted>
  <last_update_submitted_qc>September 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

